


The story of Aphea.Bio: from frontier research to leading R&D company

Isabel Vercauteren, CEO BIOEAST Webinar - November 15, 2021





Aphea.Bio: harnessing the power of the plant microbiome

Leading R&D company

- ✓ Based in Belgium, HQ at Tech Lane Ghent, one of the largest biotech ecosystems in W-Europe
- Spin-off from VIB KULeuven UGent; incorporated in July 2017
- ✓ Strong R&D and management team of 35 FTEs
- ✓ Backed by a strong VC consortium

Development of agricultural biologicals (microbials)

- Cuperior products based on novel, natural microorganisms (bacteria, fungi, yeasts)
- Bundled assets and know-how into high-throughput R&D platform for selection of winners
- **Ambition** to become a leading player and the '**one-stop-shop**' for agricultural microbials
- Future-proof solutions for sustainable agriculture in line with Farm-to-Fork strategy, a cornerstone of the European Green Deal




Aphea.Bio's core business is to develop biocontrol and biostimulant products for cereal crops A big opportunity for farmers and investors

Cereals

- ✓ Wheat (220Mi ha globally, ~30Mi ha in Europe)
- ✓ Maize (170Mi ha globally, ~ 20Mi ha in Europe)


Biocontrol products – spray-on to complement or replace chemistry

- * Biofungicides: Septoria (leaf blotch), Fusarium (head blight) and Puccinia (yellow rust) control
- Bioinsecticides: Spodoptera (caterpillar) and Myzus (aphid) control
- Bioherbicides: Monocot and dicot weed control
- Biostimulant products seed coating to reduce use of synthetic fertilizers
 Yield increase by improved nutrient use (N & P)
- Global AgBiologicals market today is around \$8Bi, expected to grow to \$20Bi by end 2026 (CAGR 13,6%)
 Global Agricultural Biologicals Market Size, 2015-2026 (USD Billion)





From frontier research to start-up company: grant funding and seed capital




- Breakthrough and frontline research
- A creative and entrepreneurial approach
- Identification of technology and product opportunities securing POC, IP and FTO
- Conceptualizing business case
- Attracting management team and seed capital (e.g. grant funding, seed and angel investments, crowdfunding)

→ Turn transformational technologies into an impactful, well-managed high-value company



From start-up to leading R&D company: venture capital and private equity investments



- Venture capital and PE ecosystem
- Further growing innovation: Series A
- Scaling the company: Series B
- Towards commercialization: Series C
- Formation of strong investment consortia

→ Internationalization of Aphea.Bio and preparation for market launch





Thank you



www.aphea.bio

Technologiepark 21 9052 Gent | Belgium

info@aphea.bio